RYR1 and myopathy: The β-agonist salbutamol has been recently studied as a pharmacological agent in the treatment of RYR1-related myopathies with encouraging results [82], however, results of this pilot study will have to be validated in a larger randomized controlled trial as a basis for future recommendations.